Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Working Capital Changes (2023 - 2025)

Monte Rosa Therapeutics' Other Working Capital Changes history spans 3 years, with the latest figure at $6.8 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 91.39% year-over-year to $6.8 million; the TTM value through Dec 2025 reached $7.5 million, down 90.98%, while the annual FY2025 figure was $7.5 million, 90.98% down from the prior year.
  • Other Working Capital Changes reached $6.8 million in Q4 2025 per GLUE's latest filing, up from -$941000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $78.4 million in Q4 2024 to a low of -$7.4 million in Q2 2023.
  • Average Other Working Capital Changes over 3 years is $11.7 million, with a median of $2.0 million recorded in 2024.
  • Peak YoY movement for Other Working Capital Changes: soared 112.82% in 2024, then crashed 155.39% in 2025.
  • A 3-year view of Other Working Capital Changes shows it stood at $40.0 million in 2023, then skyrocketed by 96.09% to $78.4 million in 2024, then tumbled by 91.39% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Other Working Capital Changes are $6.8 million (Q4 2025), -$941000.0 (Q3 2025), and $1.7 million (Q2 2025).